Personalis (NASDAQ:PSNL) CFO Aaron Tachibana Sells 51,251 Shares

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 51,251 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the sale, the chief financial officer owned 198,833 shares in the company, valued at $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The stock was sold at an average price of $12.01, for a total value of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The stock was sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $13.02 on Friday. Personalis, Inc. has a 52 week low of $3.84 and a 52 week high of $13.37. The company has a market cap of $1.36 billion, a PE ratio of -12.76 and a beta of 2.28. The firm has a 50 day simple moving average of $8.42 and a 200 day simple moving average of $8.29.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, equities analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd boosted its position in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. Legal & General Group Plc acquired a new position in Personalis during the 2nd quarter worth about $30,000. International Assets Investment Management LLC bought a new stake in Personalis during the 4th quarter worth about $31,000. BNP Paribas Financial Markets grew its holdings in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth acquired a new stake in Personalis in the 1st quarter valued at about $47,000. 61.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on PSNL. Morgan Stanley decreased their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Needham & Company LLC upped their target price on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. BTIG Research cut their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Personalis presently has an average rating of “Moderate Buy” and an average target price of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.